Rigel Pharmaceuticals RIGL Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 93.4%+3.7pp | 93.3%+3.7pp | 93.1%+3.7pp | 91.5%-0.9pp | 89.6%-3.6pp | |
| Operating margin | 41.6%+19.9pp | 42.6%+29.1pp | 42.2%+37.4pp | 39%+47.5pp | 21.6%+35.5pp | |
| Net margin | 121.5%+103pp | 124.7%+115pp | 40.2%+38.2pp | 36.5%+48.0pp | 18.3%+35.4pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×-0.5× | 0.9×-0.4× | 1.5×+0.2× | 1.6×+0.5× | 1.3×+0.4× | |
| Liquidity | ||||||
| Current ratio | 2.6×+0.4× | 2.4×+0.3× | 2.3×+0.3× | 2×+0.4× | 2.2×+0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×— | 0.2×— | 0×— | —— | —— | |
| Net debt / EBITDA | 0.3×— | 0.3×— | -0.4×— | -0.5×— | —— | |
| Per Share | ||||||
| Book value per share | $20.31+1,888% | $20.78+11,078% | $6.14+840% | $4.51+365% | $1.02+157% | |
| Valuation | ||||||
| Market capitalization | $684.39M+102% | $777.42M+162% | $508.16M+78.5% | $334.21M+132% | $321.35M+23.8% | |
| Price / earnings | 1.9×-7.2× | 2.1×— | 4.5×— | 3.4×— | —— | |
| Price / sales | 2.3×+0.6× | 2.6×+1.0× | 1.8×0.0× | 1.2×+0.1× | 1.6×-0.6× | |
| Price / book | 1.7×-16.5× | 2×— | 4.3×— | —— | —— | |
| EV / EBITDA | 5.7×-0.6× | 6.4×— | 3.8×— | 2.6×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Rigel Pharmaceuticals's profit margins?
- Rigel Pharmaceuticals (RIGL) runs a 93.4% gross margin and a 41.6% operating margin, with a 121.5% net margin.
- Where do Rigel Pharmaceuticals's ratios come from?
- Every ratio is computed from Rigel Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
